Retour
45
Fourchette du Jour
9,81 €
10,00 €
Fourchette 52 Semaines
1,50 €
12,53 €
Volume
1 000
Moyenne 50J / 200J
10,12 €
/
8,12 €
Clôture Précédente
10,00 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (626 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 8,2 | 0,4 |
| P/B | 2,8 | 2,9 |
| ROE % | 25,5 | 3,8 |
| Net Margin % | 21,8 | 3,9 |
| Rev Growth 5Y % | 22,1 | 10,0 |
| D/E | 1,3 | 0,2 |
Points Clés
Revenue grew 22,12% annually over 5 years — strong growth
ROE of 25,45% indicates high profitability
Net margin of 21,79% shows strong profitability
Negative free cash flow of -1,44B
P/E of 8,17 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 63,08%
Croissance
Revenue Growth (5Y)
22,12%
Revenue (1Y)85,20%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
25,45%
ROIC11,32%
Net Margin21,79%
Op. Margin22,19%
Sécurité
Debt / Equity
1,34
Current Ratio1,05
Interest Coverage0,00
Valorisation
P/E Ratio
8,17
P/B Ratio2,84
EV/EBITDA10,74
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 85,20% | Revenue Growth (3Y) | 71,55% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 22,12% | Earnings Growth (5Y) | 25,72% |
| Profitability | |||
| Revenue (TTM) | 3,17B | Net Income (TTM) | 690,24M |
| ROE | 25,45% | ROA | 12,55% |
| Gross Margin | 0,00% | Operating Margin | 22,19% |
| Net Margin | 21,79% | Free Cash Flow (TTM) | -1,44B |
| ROIC | 11,32% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 1,34 | Current Ratio | 1,05 |
| Interest Coverage | 0,00 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 8,17 | P/B Ratio | 2,84 |
| P/S Ratio | 1,78 | PEG Ratio | -0,37 |
| EV/EBITDA | 10,74 | Dividend Yield | 0,00% |
| Market Cap | 5,64B | Enterprise Value | 7,55B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3,17B | 1,71B | 1,08B | 767,78M | 1,42B |
| Net Income | 690,24M | -1,47B | -1,51B | -998,83M | 276,26M |
| EPS (Diluted) | 1,26 | -2,73 | -2,80 | -1,88 | 0,57 |
| Gross Profit | 0,0 | 1,37B | 822,99M | 497,84M | 1,36B |
| Operating Income | 702,81M | -1,37B | -1,50B | -1,05B | 162,84M |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 5,50B | 5,53B | 6,02B | 4,16B | 4,12B |
| Total Liabilities | 3,51B | 2,09B | 1,04B | 712,79M | 523,07M |
| Shareholders' Equity | 1,99B | 3,44B | 4,98B | 3,45B | 3,59B |
| Total Debt | 2,67B | 1,26B | 165,04M | 102,78M | 197,69M |
| Cash & Equivalents | 759,53M | 709,07M | 2,07B | 1,76B | 2,77B |
| Current Assets | 2,29B | 2,23B | 3,21B | 2,30B | 2,98B |
| Current Liabilities | 2,19B | 1,14B | 892,30M | 616,40M | 431,29M |
Scores de Stratégies
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#194 of 658
Activité Récente
Entré
Contrarian Investing (David Dreman)
Mar 24, 2026